TP53 and cancer: Thus, the employment of TCRm Abs recognizing p53-Y220C may be potentially useful to target solid tumors that lack T cell infiltration, especially in combination with other approaches, such as oncolytic viruses and cancer vaccines that are being evaluated to enhance T cell trafficking to tumors[87–88].